Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 189 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014', provides an overview of the Relapsed Chronic Lymphocytic Leukemia (CLL)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Relapsed Chronic Lymphocytic Leukemia (CLL)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Relapsed Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Relapsed Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Relapsed Chronic Lymphocytic Leukemia (CLL) Overview 9
Therapeutics Development 10
Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Overview 10
Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis 11
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 12
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 17
Relapsed Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 19
Bristol-Myers Squibb Company 19
Boehringer Ingelheim GmbH 20
Sanofi 21
AstraZeneca PLC 22
GlaxoSmithKline plc 23
Genentech, Inc. 24
MedImmune, LLC 25
Emergent BioSolutions Inc. 26
Infinity Pharmaceuticals, Inc. 27
Piramal Enterprises Limited 28
Novartis AG 29
Astellas Pharma Inc. 30
Astex Pharmaceuticals, Inc. 31
Celgene Corporation 32
Immunomedics, Inc. 33
TG Therapeutics, Inc. 34
Pharmacyclics, Inc. 35
MorphoSys AG 36
Threshold Pharmaceuticals, Inc. 37
Onconova Therapeutics, Inc. 38
Noxxon Pharma AG 39
LFB S.A. 40
Advancell 41
Karyopharm Therapeutics, Inc. 42
Rhizen Pharmaceuticals SA 43
AbbVie Inc. 44
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Combination Products 46
Assessment by Target 47
Assessment by Mechanism of Action 50
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 57
ibrutinib - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
duvelisib - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
venetoclax - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
venetoclax + rituximab - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
acadesine - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
AT-7519 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
otlertuzumab - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
olaptesed pegol - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
MOR-208 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
MEDI-551 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
tisagenlecleucel-T - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
afuresertib hydrochloride - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
moxetumomab pasudotox - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
FBTA-05 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
PRT-2070 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Cell Therapy for Leukemia - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
SAR-245408 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
TH-302 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
rigosertib sodium - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
P-1446 - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
IMMU-114 - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
ublituximab - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
CC-292 - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
BI-836826 - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
P-2745 - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
BMS-986016 - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
selinexor - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
TGR-1202 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
TG-1101 + TGR-1202 - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
AZD-6738 - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
GDC-0853 - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
ACP-196 - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
venetoclax + obinutuzumab - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
AGS-67E - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
Relapsed Chronic Lymphocytic Leukemia (CLL) - Recent Pipeline Updates 127
Relapsed Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 186
Relapsed Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 187
Appendix 188
Methodology 188
Coverage 188
Secondary Research 188
Primary Research 188
Expert Panel Validation 188
Contact Us 189
Disclaimer 189

List of Tables
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL), H2 2014 10
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Development by Companies, H2 2014 (Contd..1) 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Development by Companies, H2 2014 (Contd..1) 18
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H2 2014 19
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H2 2014 20
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H2 2014 21
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by AstraZeneca PLC, H2 2014 22
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by GlaxoSmithKline plc, H2 2014 23
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genentech, Inc., H2 2014 24
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by MedImmune, LLC, H2 2014 25
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Emergent BioSolutions Inc., H2 2014 26
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Infinity Pharmaceuticals, Inc., H2 2014 27
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Piramal Enterprises Limited, H2 2014 28
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H2 2014 29
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc., H2 2014 30
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 31
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H2 2014 32
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics, Inc., H2 2014 33
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by TG Therapeutics, Inc., H2 2014 34
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Pharmacyclics, Inc., H2 2014 35
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H2 2014 36
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2014 37
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Onconova Therapeutics, Inc., H2 2014 38
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Noxxon Pharma AG, H2 2014 39
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB S.A., H2 2014 40
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Advancell, H2 2014 41
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 42
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Rhizen Pharmaceuticals SA, H2 2014 43
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc., H2 2014 44
Assessment by Monotherapy Products, H2 2014 45
Assessment by Combination Products, H2 2014 46
Number of Products by Stage and Target, H2 2014 49
Number of Products by Stage and Mechanism of Action, H2 2014 52
Number of Products by Stage and Route of Administration, H2 2014 54
Number of Products by Stage and Molecule Type, H2 2014 56
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics - Recent Pipeline Updates, H2 2014 127
Relapsed Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H2 2014 186
Relapsed Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H2 2014 187